Effect of the Antioxidant Lipoic Acid in Aortic Phenotype in a Marfan Syndrome Mouse Model

Table 5

Evolution of structural aorta remodeling in WT and MFS mice with 6 months of age after losartan or lipoic acid treatments.

	Untreated		Losartan treatment		Lipoic acid treatment
	WT6	MFS6	WT6	MFS6	WT6	MFS6
	()	()	()	()	()	()
Aortic arch
Thickness (mm^2)	28 ± 1	40 ± 3^a	19 ± 4^b	23 ± 3^b	32 ± 2	48 ± 3^c–e
Total CVF (%)	11 ± 2	23 ± 6^a	11 ± 1^f	10 ± 1^b	18 ± 2	29 ± 2^c–e,g
Collagen I/III ratio	1.0 ± 0.1	12.1 ± 4.1^c	1.0 ± 0.1^i	5.2 ± 0.4^c,d	0.8 ± 0.1^e,i	9.2 ± 1.7^c,d,h
EFD (number/mm^2)	0.01 ± 0.03	1.30 ± 0.08^c	0.01 ± 0.01^i	0.04 ± 0.01^i	0.02 ± 0.01^i	1.70 ± 0.02^c–e,h
FBN1 (area %)	101 ± 1	33 ± 5^c	94 ± 1^i	45 ± 5^c,d	110 ± 2^e,i	39 ± 2^c,d,h
Thoracic aorta
Thickness (mm^2)	25 ± 1	26 ± 4	25 ± 2	20 ± 1	27 ± 1	33 ± 1
Total CVF (%)	15 ± 2	19 ± 1	12 ± 3	20 ± 3	16 ± 1	21 ± 6^c–e,j
Collagen I/III ratio	1.0 ± 0.1	3.1 ± 0.7^c	1.3 ± 0.2^i	1.5 ± 0.1^c,d	1.5 ± 0.1^e,i	3.1 ± 0.2^c,d,f,h
EFD (number/mm^2)	0.10 ± 0.02	0.92 ± 0.13^c	0.11 ± 0.01^i	0.38 ± 0.01^i	0.13 ± 0.02^i	1.01 ± 0.25^c–e,h
FBN1 (area %)	100 ± 1	48 ± 5^c	90 ± 1^i	57 ± 3^c,d	101 ± 1^e,i	39 ± 3^c,d,h
Abdominal aorta
Thickness (mm^2)	23 ± 1	34 ± 3^k	27 ± 6^f	20 ± 2	23 ± 3	34 ± 4
Total CVF (%)	10 ± 1	31 ± 2^a	10 ± 1^f	12 ± 2^f	11 ± 2	32 ± 3^c,d,f,h,i
Collagen I/III ratio	1.1 ± 0.1	11.7 ± 3.2^c	0.8 ± 0.1^i	1.1 ± 0.1^c,d	1.0 ± 0.3^e,i	10.2 ± 0.1^c,d,f,h
EFD (number/mm^2)	0.10 ± 0.01	0.95 ± 0.19^c	0.11 ± 0.01^b	0.50 ± 0.10^i	0.12 ± 0.2	1.40 ± 0.50^c–e,h
FBN1 (area %)	100 ± 2	44 ± 6^c	87 ± 1^i	31 ± 6^c,d	98 ± 4^e,i	38 ± 3^c,d,h

WT: wild type; MFS: Marfan syndrome; 6: 6 months of age; CVF: collagen volume fraction; EFD: elastic fiber disruptions; FBN 1: fibrillin-1; ^a versus untreated WT6; ^b versus untreated MFS6; ^c versus untreated WT6; ^d versus losartan treatment WT6; ^e versus losartan treatment MFS6; ^f versus untreated MFS6; ^g versus lipoic acid treatment WT6; ^h versus lipoic acid treatment WT6; ⁱ versus untreated MFS6; ^j versus lipoic acid treatment WT6; ^k versus untreated WT6.